[Effect of ritmilen on myocardial refractility and cardiac impulse conduction in patients with paroxysmal tachycardia].
By choosing antiarrhythmic therapy, ritmilen, 3 mg/kg, was given to 30 patients with atrial, atrioventricular, reciprocal and ventricular tachycardias. The agent was found to have the highest effect on atrial myocardial refractoriness in patients with atrial tachycardias and on ventricular refractoriness in patients with ventricular tachycardias (longer effective and functional refractory periods). Intraventricular pathways are the major site of ritmilen's effect on anterograde conduction. Profound changes were found in patients with atrial and ventricular tachycardias. The cholinolytic action of ritmilen on the atrioventricular node was detected in 20% of the patients, whereas sinus rhythm increased in 90%, which may be attributable to asymmetric vagus innervation of sinoatrial and atrioventricular nodes.
Grishkin
Iu N
IuN
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004206:Disopyramide / Q000627:therapeutic use*; D006325:Heart Atria / Q000187:drug effects / Q000294:innervation; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006352:Heart Ventricles / Q000187:drug effects / Q000294:innervation; D006801:Humans; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects* / Q000502:physiology; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000188:drug therapy* / Q000503:physiopathology; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D004206:Disopyramide
Vliianie ritmilena na refrakternost' miokarda i provedenie serdechnogo impulsa u bol'nykh s paroksizmal'nymi takhikardiiami.